ReportsAdverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: A prospective study of 54 patients☆,☆☆,★,★★
Section snippets
Patients
During a 2-month period, from May to June 2001, all consecutive patients previously included in 3 phase 2 trials of imatinib and treated at our institution as inpatients or outpatients were included in this dermatologic study. Patients more than 18 years of age were referred for the treatment of CML or Ph1-positive ALL. In the different protocols, patients had failed to respond to, had relapsed on, or had major side effects while receiving IFN. Patients who had progressed to accelerated phase
Patients
A total of 54 patients (31 males and 23 females) were included in our study. All but 2 patients had CML. The major reasons for including patients in the imatinib trials were hematologic resistance or relapse while receiving IFN (26 of 52). The mean duration of the hematologic malignancy was 46.6 month (± 37.9 SD), ranging from 2.5 to 192 months. Imatinib was administered for a mean of 4.5 months (± 2.9 SD) at an initial dose of 400 or 600 mg/d, according to stage of disease. The daily dose at
Discussion
The purpose of this study was to define the prevalence and the clinical and pathologic patterns of adverse cutaneous reactions induced by imatinib. This molecule selectively inhibits the enzymatic activity of several TKs including the TK associated with BCR-ABL, the receptor of platelet-derived growth factor and c-kit.
In patients with Ph1-positive leukemias, the use of imatinib was associated with a high rate of adverse cutaneous reactions. Rash and edema were the most common adverse effects
Acknowledgements
We are indebted to P. Wolkenstein and John Ford for their helpful review of the manuscript.
References (20)
- et al.
Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal cancers: a phase I study
Lancet
(2001) - et al.
Imatinib for chronic myeloid leukemia: a nice mess
Lancet
(2001) - et al.
The paracrine role of stem cell factor/c-kit signaling in the activation of human melanocytes in ultraviolet-B-induced pigmentation
J Invest Dermatol
(2001) - et al.
The SCF/Kit path-way plays a critical role in the control of normal human melanocyte homeostasis
J Invest Dermatol
(1999) - et al.
The biology of chronic myeloid leukemia
N Engl J Med
(1999) - et al.
Induction of chronic myelogenous leukemia in mice by the P210 bcr/abl gene of Philadelphia chromosome
Science
(1990) - et al.
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
N Engl J Med
(2001) - et al.
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
N Engl J Med
(2001) - et al.
Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia
N Engl J Med
(2001) - et al.
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Nat Med
(1996)
Cited by (207)
Commonly prescribed medications associated with alopecia
2023, Journal of the American Academy of DermatologyPityriasis Rosea-like Eruption Induced by Imatinib in a Patient With a Gastrointestinal Stromal Tumor
2021, Actas Dermo-SifiliograficasThe blue palate—A case series of imatinib-related oral pigmentation and literature review
2021, Oral Surgery, Oral Medicine, Oral Pathology and Oral RadiologyCitation Excerpt :The shortest duration of imatinib treatment was 1 month,41 with the longest treatment reported at 15 years42; 9 cases did not report a duration.16,20,21,32,36,43 Intraoral pigmentation was reported in 98 cases; the hard palate was the most commonly reported site (92 cases), with mucosa (2 cases), teeth (2 cases), and gingivae (2 cases).2-5,10-12,15,16,20-45 Color of pigmentation was a diverse finding, including alone or a combination of gray, blue, black, brown, and purple.2-5,10-12,15,16,20-23,25-45
Oncolytic Drugs
2020, Drug-Induced Ocular Side Effects, Eigtht EditionIn vitro PK/PD modeling of tyrosine kinase inhibitors in non-small cell lung cancer cell lines
2024, Clinical and Translational Science
- ☆
Funding sources: None.
- ☆☆
Conflict of interest: None identified.
- ★
Reprint requests: Jean Revuz, MD, Department of Dermatology, Henri Mondor Hospital, F-94010 Créteil Cedex, France. E-mail: [email protected].
- ★★
0190-9622/2003/$30.00 + 0